Advanced Therapies & Expo 2020 on September 9
CIRM 2020 Grantee Meeting on September 14Collaborations That Transform MS Webinar on September 24 NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it will deliver virtual presentations during Advanced Therapies & Expo 2020, September 9, at the 2020 CIRM Grantee Meeting, September 14, 2020, and at the WuXi Apptec Collaborations That Transform Meeting focusing on Multiple Sclerosis, September 24, 2020.Participants can view the presentations via the event links and those unable to join will have access to an archived link on the Company’s Events and Presentation webpage after the conclusion of the conferences.
BrainStorm is the recipient a non-dilutive grant of $16 million by California Institute for Regenerative Medicine (CIRM) to support the ongoing Phase 3 study of NurOwn^®, for the treatment of amyotrophic lateral sclerosis (ALS).   About BrainStorm Cell Therapeutics Inc. 
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.comCONTACTS Investor Relations:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Phone: +1 646-465-1138
[email protected]Media:
Paul Tyahla
SmithSolve
Phone: + 1-973-713-3768
[email protected]

Bay Street News